Brind.

Analysis Compares Applied DNA Sciences and Bolt Biotherapeutics Stock Profiles

1 report, 1 independent Updated Tue 00:00
AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

A comparison of Applied DNA Sciences and Bolt Biotherapeutics found that Bolt Biotherapeutics has a beta of 1, indicating its share price volatility is similar to the S&P 500. In contrast, Applied DNA Sciences has a beta of 0.63, suggesting its share price is 37% less volatile than the S&P 500. Applied DNA Sciences reports higher earnings than Bolt Biotherapeutics, although it has lower revenue.

From dailypolitical.com

Why it matters

Some supportBrind's analysis of the reports

The comparison highlights differences in risk and valuation between the two small-cap healthcare companies. Bolt Biotherapeutics is trading at a lower price-to-earnings ratio than Applied DNA Sciences, and Bolt Biotherapeutics has significantly higher institutional ownership.

From dailypolitical.com

Who's involved

  • Applied DNA SciencesAmerican high-technology company being analyzed for its investment profile
  • Myriad GeneticsAmerican biotechnology company identified as a competitor to Applied DNA Sciences

Keep exploring

The entities involved

Coverage

Newest first; wire copies grouped